Scheduling Format Announced for CNBC Telecast Featuring DATATRAK International

Scheduling Format Announced for CNBC Telecast Featuring DATATRAK International

CLEVELAND, Sept. 30 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (NASDAQ:DATA), the leading and most experienced Application Service Provider ("ASP") in the Electronic Data Capture ("EDC") industry today announced that it has received initial airing schedules for the CNBC segment highlighting the Company and focused on the increasing use of technology in global clinical trials. This television production will be aired once nationally in the United States and Europe and will be replayed approximately 100 times in 25 leading markets throughout the United States. All telecasts will appear on CNBC.

DATATRAK has placed a schedule of when this segment will be aired in each respective geographic market on the "Events" page of its web site at www.datatrak.net. The initial airing will be shown in the Cleveland, Ohio market every Sunday in October at 6:30 P.M. immediately following the CNN Headline News Block. Complete production schedules are currently unknown for all markets; however, the Company will update the information on its web site as soon as the producer communicates the exact showing dates and times. Those interested in viewing this segment should periodically review this area of the Company's web site for the most updated information regarding when this might air in their location.

"We are pleased that DATATRAK could take a leading role in educating society on the advantages of technology use in global clinical trials through this informational segment, especially on such a respected venue as CNBC," stated Dr. Jeffrey A. Green, President and Chief Executive Officer of DATATRAK International, Inc. "This exposure should be beneficial not only for our Company, but for the entire market of providers attempting to elevate the standard of practice for the most expeditious and safe management of information involving investigational drugs and devices. This production emphasizes the economic advantages of EDC use in clinical trials, but more importantly addresses how this technology can have a positive impact on patient safety and offer a risk reduction strategy for developers of investigational drugs and devices compared to traditional paper methods."

About DATATRAK

DATATRAK International, Inc. is a worldwide ASP for the EDC industry. The Company provides a suite of software products supporting the use of DATATRAK EDC(R) and related services to the pharmaceutical, biotechnology, and medical device industries. DATATRAK EDC(R) was developed in order to deliver clinical research data from investigative sites to clinical trial sponsors faster and more efficiently than conventional, manual methods. DATATRAK EDC(R) can be deployed worldwide in either a distributed platform using laptop computers or in a centralized environment using the Internet. DATATRAK EDC(R) software and its earlier versions have successfully supported many international clinical studies involving thousands of clinical research sites and encompassing tens of thousands of patients in 49 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 14 separate drugs that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio and Bonn, Germany. Its common shares are listed on the Nasdaq Stock Market under the symbol "DATA." Visit the DATATRAK International, Inc. web site at www.datatrak.net or www.datatraknet.de.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. Factors that may cause actual results to differ materially from those in the forward-looking statements include the ability of the Company to absorb corporate overhead and other fixed costs in order to successfully market the DATATRAK EDC(R) software; the development and fluctuations in the market for EDC technology; the degree of the Company's success in obtaining new contracts; the timing of payments from customers and the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; governmental regulation; the early stage of the Company's EDC business and operations; and general economic conditions. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry.

Source: DATATRAK International, Inc.

CONTACT: Jeffrey A. Green, Pharm.D., FCP, President & Chief Executive
Officer, +1-440-443-0082, Ext. 112, or Terry C. Black, Chief Financial
Officer, +1-440-443-0082 Ext. 110, both of DATATRAK International; or Neal
Feagans, Investor Relations, Feagans Consulting, Inc., +1-303-449-1184

Web site: http://www.datatrak.net/

-------
Profile: intent